Drugs / SEA-BCMA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03582033 | Nov 2018 → Nov 2023 | plasma cell myeloma | Seagen Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03266692 | Feb 2018 → Oct 2019 | plasma cell myeloma | Cogent Biosciences, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEA-BCMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03266692 ↗ |
| Known as | Anti-bcma antibody sea-bcma | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594496 ↗ |
| Modality | Monoclonal antibody | “SEA-BCMA (a monoclonal antibody)” NCT03266692 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenously)” NCT03582033 ↗ |